Back

Dose-dependent effects of aficamten vs metoprolol in MAPLE-HCM

11 May 2026 (16:06 - 16:18)
Organised by: Logo
Congress Presentation Part of: Advances in cardiomyopathies Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

4 More presentations in this session

Presentation thumbnail
sTTR variability and outcomes in ATTR-CM
Doctor S. Selvaraj (Durham, US)
Slides Video
Presentation thumbnail
BHB/HRS-1893 in non-obstructive hypertrophic cardiomyopathy
Doctor L. Wang (Beijing, CN)
Slides Video
Presentation thumbnail
RESOLVE-HCM: perhexiline on regression of LVH in symptomatic HCM
Professor J. Selvanayagam (Adelaide, AU)
Slides Video
Presentation thumbnail
ATTRibute-CM: outpatient worsening heart failure in ATTR-CM
Professor M. Fontana (London, GB)
Slides Video

Access the full session

Session thumbnail
Advances in cardiomyopathies
Video

The Event

Event poster

Heart Failure 2026

11 May 2026 16:06 CET
You may be interested in
thumbnail
Congress Presentation
MAPLE-HCM: aficamten vs metoprolol in oHCM
thumbnail
Congress Session
Fast forwarding care: advancements in treatment for oHCM and clinical practice advantages with aficamten
thumbnail
Congress Presentation
Effects of bisoprolol and verapamil in non-obstructive hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources